Par Pacific signals 2026 priorities with $915M liquidity and renewed focus on renewables, cost reduction, and strategic growth

Ooops... Something went wrong while loading this page.

Novo bets up to $2.1B in Vivtex deal for oral obesity and diabetes drugs

Novo Nordisk (NVO) stock is in focus as the company teams up with Vivtex in a $2.1B deal to develop next-gen oral biologics for obesity and diabetes. Read more here.
Hoodline

San Antonio AI Researchers Sound Alarm On Phantom Package Trap

UTSA: ~20% of AI-suggested packages don't exist. Slopsquatting could let attackers slip malicious libs into projects.

Kalshi reveals insider trading case against editor for MrBeast

With prediction markets booming, so have concerns about insider trading. Now, Kalshi has disclosed its first public actions against accounts suspected of trading on confidential information.